---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-029646"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2023-06-23T23:59:59+00:00"
generated_at: "2026-06-13T18:39:18.231640+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Heron Therapeutics appoints Ira Duarte as CFO effective June 16, 2023

## Summary
- Ira Duarte named CFO; previously CFO of Veloxis Pharmaceuticals and held finance roles at BioDelivery Sciences, Chiesi USA, and Ernst & Young.
- Compensation includes $500K base salary, $250K target bonus (pro-rated for 2023), and inducement award of options for 800K shares, 50K RSUs, and performance options for up to 500K shares.
- Inducement award granted outside 2007 Plan with four-year vesting for options and RSUs; performance options vest based on stock price goals.
- Duarte also holds a board seat at TerrAscend Corp. since December 2022 and is a CPA with a BS in Accounting from Florida Atlantic University.

## SEC filing metadata
- accession: 0000950170-23-029646
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2023-06-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000095017023029646/0000950170-23-029646-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000095017023029646/hrtx-20230616.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-029646
- JSON: https://secwatch.observer/filing/0000950170-23-029646.json
- Plain text: https://secwatch.observer/filing/0000950170-23-029646.txt

## Key facts
- Executive change
  Ira Duarte was appointed as Chief Financial Officer at HERON THERAPEUTICS, INC. /DE/.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: appointed Ira Duarte as Chief Financial Officer, effective June 16, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/818033/000095017023029646/0000950170-23-029646-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.